Respiratory Syncytial Virus (RSV) Prophylaxis Market is projected to grow to USD 7.95 billion in 2034

The global Respiratory Syncytial Virus (RSV) Prophylaxis Market is experiencing rapid expansion due to the breakthrough approvals of long-acting monoclonal antibodies and adult vaccines. In 2024, the market reached USD 1.82 billion, driven primarily by the commercial success of Beyfortus (nirsevimab) for infants and the launch of Arexvy (GSK) and Abrysvo (Pfizer) for older adults.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73648

RSV poses a significant global burden, especially in infants under 12 months, older adults above 60 years, and individuals with chronic cardiopulmonary conditions. Growing awareness campaigns, broader immunization recommendations, and government-backed RSV prevention programs have accelerated the adoption of prophylaxis solutions across all major regions.

By 2034, the market is projected to grow to USD 7.95 billion, expanding at a strong 15.8% CAGR, driven by expanded pediatric coverage, adult vaccination programs, pipeline antibody candidates, and increased RSV surveillance capabilities worldwide.

Key Market Drivers
• Rapid adoption of nirsevimab following widespread recommendations for all infants
• Strong demand for RSV vaccines among older adults and high-risk populations
• Increasing global RSV hospitalization rates in infants and seniors
• Growth in clinical development of long-acting antibodies and novel prophylactic technologies
• Expansion of immunization reimbursement frameworks across developed markets
• Strong post-pandemic focus on respiratory disease prevention
• Technological advancements in protein subunit vaccines, mRNA platforms, and viral vector systems

Market Restraints
• High cost of biologics and limited affordability in low-income markets
• Logistical challenges in delivering monoclonal antibodies for infants
• Limited long-term real-world data on adult RSV vaccines
• Concerns about vaccine hesitancy in certain regions
• Slow approval timelines in emerging economies

Market Segmentation
By Product Type
• Monoclonal Antibodies
o Nirsevimab (Beyfortus)
o Palivizumab (Synagis)
o Next-generation mAbs (Pipeline)
• Vaccines
o Adult RSV Vaccines (Arexvy, Abrysvo)
o Maternal RSV Vaccines
o Pediatric RSV Vaccines (Pipeline)

By Target Population
• Infants (Term and Preterm)
• Pregnant Women
• Older Adults (≥60 Years)
• Adults with Chronic Heart or Lung Conditions
• Immunocompromised Individuals

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Pediatric Clinics
• Vaccination Centers
• Online Pharmacies (limited, expanding)

By End User
• Hospitals
• Specialty Clinics
• Community Health Centers
• Home Healthcare Providers

Explore Full Report here: https://exactitudeconsultancy.com/reports/73648/respiratory-syncytial-virus-prophylaxis-market

Regional Analysis
North America
• Market share (2024): ~45%
• U.S. leads due to high uptake of Arexvy and universal infant coverage for Beyfortus.
• Strong reimbursement and RSV immunization guidelines accelerate adoption.
• Expected to maintain dominance through 2034.
Europe
• Market share (2024): ~30%
• Rapid expansion of infant RSV antibody administration across EU5.
• High adoption of adult RSV vaccines and maternal immunization programs.
• EMA approvals and government-funded RSV prevention initiatives support growth.
Asia Pacific
• Fastest-growing region (CAGR: ~19% through 2034)
• Increasing RSV burden in infants and seniors in China, India, Japan, and South Korea.
• Expanding pediatric immunization budgets and adult vaccine rollouts.
• Growing manufacturing capabilities for biologics.
Latin America and Middle East/Africa
• Rising RSV awareness and improving vaccination infrastructure.
• Growing demand for cost-effective prophylaxis, particularly for infants.
• Gradual introduction of adult RSV vaccines expected over the next decade.

Competitive Landscape (20 Key Players)
1. Sanofi (Beyfortus)
2. AstraZeneca (Co-developer of nirsevimab)
3. GSK plc (Arexvy)
4. Pfizer Inc. (Abrysvo)
5. Moderna, Inc. (mRNA RSV vaccines in pipeline)
6. Johnson & Johnson / Janssen
7. Novavax Inc.
8. Bavarian Nordic
9. Merck & Co.
10. Roche / Genentech
11. CSL Seqirus
12. Sinovac Biotech
13. Serum Institute of India
14. Beijing Zhifei Longcom
15. BioNTech SE (mRNA RSV pipeline)
16. VBI Vaccines
17. SBI Biotech
18. Emergent BioSolutions
19. AbbVie (Historical stakeholder in Synagis)
20. GlaxoSmithKline Biologicals
These companies are advancing adult immunization programs, monoclonal antibody development, pediatric RSV prevention strategies, and next-generation RSV vaccine technologies.

Recent Developments
• 2024: Beyfortus demand surged due to expanded universal infant RSV prophylaxis programs in North America and Europe.
• 2024: GSK's Arexvy recorded strong Q1 and Q2 adoption across adult populations in over 20 countries.
• 2023-2024: Pfizer expanded Abrysvo availability for pregnant women to reduce infant RSV hospitalization rates.
• 2024: Multiple biopharma companies initiated trials for second-generation RSV mAbs with improved half-life.
• 2023: EMA and FDA issued updated RSV immunization guidelines for infants and seniors.
• APAC: India and China began scaling RSV surveillance programs to guide future vaccine distribution.

Opportunities
• Expansion of RSV prophylaxis into low- and middle-income countries
• Development of combination vaccines (RSV + influenza + COVID-19)
• Use of mRNA platforms for faster, variant-adapted RSV vaccines
• Increasing adoption of maternal immunization to protect newborns
• Growing clinical trials for long-acting antibody therapeutics
• Integrating RSV vaccination into routine adult immunization schedules
• Rising investments in pediatric healthcare infrastructure

Conclusion
The global RSV prophylaxis market is entering a high-growth phase, driven by landmark approvals of long-acting antibodies, new adult vaccines, and increased awareness of RSV severity in infants and seniors. With an expected market size of USD 7.95 billion by 2034 and a 15.8% CAGR, the sector represents one of the most promising areas in infectious disease prevention.

North America will continue to dominate, while Asia Pacific will see the fastest adoption due to rising RSV incidence and expanding healthcare access. The next decade will also see significant innovation across monoclonal antibodies, mRNA vaccines, maternal immunization, and combination respiratory vaccines.

This report is also available in the following languages : Japanese (RSウイルス予防市場), Korean (호흡기 세포융합 바이러스 예방 시장), Chinese (呼吸道合胞病毒预防市场), French (Marché de la prophylaxie du virus respiratoire syncytial), German (Markt für Prophylaxe gegen das Respiratorische Synzytialvirus), and Italian (Mercato della profilassi del virus respiratorio sinciziale), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73648

Our More Reports:
Topical Anti-infective Drugs Market
https://exactitudeconsultancy.com/reports/75276/topical-anti-infective-drugs-market

Hemophilia B Patient Pool Analysis Market
https://exactitudeconsultancy.com/reports/71461/hemophilia-b-patient-pool-analysis-market

Hereditary Angioedema Market
https://exactitudeconsultancy.com/reports/71655/hereditary-angioedema-market

Antimalarial Drugs Market
https://exactitudeconsultancy.com/reports/72355/antimalarial-drugs-market.p

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.